Study of SR-8541A plus two immunotherapies for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread and cannot be removed by surgery.
- Your tumor is not MSI-high or dMMR (a specific genetic type).
- You have already tried at least one type of chemotherapy for your metastatic cancer.
- You are able to provide a tumor tissue sample (from a past biopsy or a new one) for testing.
- Your kidney, liver, and blood cell counts are working well enough (checked by standard lab tests).
- You are willing to use highly effective birth control during and for 3 months after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three new drugs (SHR-1701, SHR2554, and BP102) for people with metastatic colorectal cancer. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial is testing three different combinations of existing and new drugs for advanced or metastatic colorectal cancer that hasn't improved with standard treatments or has spread to the liver. The goal is to see which combination works best and is safe for patients like you.
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
This study tests a new combination of three drugs for advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow down the cancer's growth.
This trial tests a combination of two drugs, sintilimab (an immunotherapy that helps the immune system fight cancer) and gossypol acetate (a drug that may make cancer cells more vulnerable), for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can slow or stop the cancer.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
Hear when a new Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.